GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices: London, UK Saturday, April 19, 2025, 13:00 Hrs ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Global biopharma company GSK has awarded nearly $2 million in funding through its COiMMUNITY Initiative grant program to 15 organizations focused on improving adult immunization across the ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

Moody's Ratings has upgraded the long-term issuer rating of Haleon plc and its guaranteed subsidiaries to A3 from Baa1. The rating agency also upgraded the rating on Haleon's backed senior unsecured ...

Me’s debacle should be a major wake-up call, reminding policymakers and all of us of the risks of giving access to our ...

GSK sued Pfizer in 2023, arguing that the New York-based company's vaccine infringed GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer began working on its RSV program ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 ...